Continuing our previous study focusing on the relationship between MK2 and outcomes of MM patients in the APEX cohort, which was an independent cohort of MM patients (17), we further confirmed that MK2 acts as a valuable diagnostic and prognostic marker in MM. The gene discussed is MAPKAPK2; the disease is Miyoshi myopathy.